Premature Ejaculation - Pipeline Review, H2 2020
Premature Ejaculation - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H2 2020, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape.
Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Ejaculation - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.
Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Premature Ejaculation - Pipeline Review, H2 2020, provides an overview of the Premature Ejaculation (Male Health) pipeline landscape.
Premature ejaculation (PE) is also known as rapid ejaculation, is the most common type of sexual dysfunction in men. Ejaculation is controlled by the central nervous system. This happens when sexual stimulation and friction provide impulses that are delivered to the spinal cord and into the brain. The predisposing factors include erectile dysfunction, stress and certain medications that influence the action of chemical messengers in the brain (psychotropics) may contribute to premature ejaculation. Treatment includes topical anesthetic creams and antidepressants.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Premature Ejaculation - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Premature Ejaculation (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Premature Ejaculation (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Premature Ejaculation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.
Premature Ejaculation (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Premature Ejaculation (Male Health).
- The pipeline guide reviews pipeline therapeutics for Premature Ejaculation (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Premature Ejaculation (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Premature Ejaculation (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Premature Ejaculation (Male Health)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Premature Ejaculation (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Premature Ejaculation (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Premature Ejaculation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Ejaculation - Companies Involved in Therapeutics Development
Ctcbio Inc
Dicot AB
Ixchelsis Ltd
NeuroHealing Pharmaceuticals Inc
Plethora Solutions Holdings Plc
Premature Ejaculation - Drug Profiles
(clomipramine hydrochloride + sildenafil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cligosiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
libiguins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
Featured News & Press Releases
Jul 23, 2020: CHMP recommended a change in classification status for Fortacin
Sep 19, 2019: Plethora Pharma Solutions receives CHMP positive opinion for Senstend
Jul 11, 2018: Dicot signs extended Service Agreement with Anthem Biosciences for Preclinical Development of Libiguin
Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation
Nov 11, 2014: Plethora Solutions Provides Company Update
Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
Mar 11, 2014: Plethora Solutions Provides Company update
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
Dec 19, 2011: Plethora Provides Update On PSD502
Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Premature Ejaculation - Overview
Premature Ejaculation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Premature Ejaculation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Premature Ejaculation - Companies Involved in Therapeutics Development
Ctcbio Inc
Dicot AB
Ixchelsis Ltd
NeuroHealing Pharmaceuticals Inc
Plethora Solutions Holdings Plc
Premature Ejaculation - Drug Profiles
(clomipramine hydrochloride + sildenafil citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cligosiban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
libiguins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Premature Ejaculation - Dormant Projects
Premature Ejaculation - Discontinued Products
Premature Ejaculation - Product Development Milestones
Featured News & Press Releases
Jul 23, 2020: CHMP recommended a change in classification status for Fortacin
Sep 19, 2019: Plethora Pharma Solutions receives CHMP positive opinion for Senstend
Jul 11, 2018: Dicot signs extended Service Agreement with Anthem Biosciences for Preclinical Development of Libiguin
Jan 25, 2016: Ixchelsis Announces Positive Clinical Proof of Concept Results for IX-01 in Treating Premature Ejaculation
Nov 11, 2014: Plethora Solutions Provides Company Update
Oct 07, 2014: PSD502 To Be Marketed As Fortacin Throughout The EU
Mar 26, 2014: Plethora Solutions Announces Manufacturing Appointment
Mar 11, 2014: Plethora Solutions Provides Company update
Nov 19, 2013: Plethora Solutions Receives European Commission Approval For PSD502 To Treat Premature Ejaculation
Sep 19, 2013: Plethora Solutions Receives CHMP Positive Opinion For Lidocaine/Prilocaine Plethora For Treatment Of Primary Premature Ejaculation
Jul 01, 2013: AGM Statement & PSD502 Regulatory Update
Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
Dec 19, 2011: Plethora Provides Update On PSD502
Jun 01, 2010: Shionogi Pharma Presents Data On PSD502 For Primary Premature Ejaculation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Premature Ejaculation, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Premature Ejaculation - Pipeline by Ctcbio Inc, H2 2020
Premature Ejaculation - Pipeline by Dicot AB, H2 2020
Premature Ejaculation - Pipeline by Ixchelsis Ltd, H2 2020
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2020
Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H2 2020
Premature Ejaculation - Dormant Projects, H2 2020
Premature Ejaculation - Discontinued Products, H2 2020
Number of Products under Development for Premature Ejaculation, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Premature Ejaculation - Pipeline by Ctcbio Inc, H2 2020
Premature Ejaculation - Pipeline by Dicot AB, H2 2020
Premature Ejaculation - Pipeline by Ixchelsis Ltd, H2 2020
Premature Ejaculation - Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2020
Premature Ejaculation - Pipeline by Plethora Solutions Holdings Plc, H2 2020
Premature Ejaculation - Dormant Projects, H2 2020
Premature Ejaculation - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Premature Ejaculation, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
Number of Products under Development for Premature Ejaculation, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Types, H2 2020
